Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Phase II Clinical Study of HX008 in Combination With Bevacizumab or Lenvatinib in Patients With Advanced Hepatocellular Carcinoma (HCC)

NCT04741165 is registered in ClinicalTrials.gov with Taizhou Hanzhong biomedical co. LTD as lead sponsor.

NCT NCT04741165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04741165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Phase II Clinical Study of HX008 in Combination With Bevacizumab or Lenvatinib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Lead sponsor
Taizhou Hanzhong biomedical co. LTD
Phase
Phase 2
Overall status
Unknown status
Start date
January 7, 2021
Completion date
October 30, 2022
Enrollment
72 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma